[1] 顾睿, 李瑞明, 张兰兰, 等. 普洱茶化学成分及药理研究进展[J]. 天津药学, 2011, 23(1): 47-51. Gu R, Li R M, Zhang L L, et al.Advances in study on chemical composition and pharmacological properties of pu-erh tea[J]. Tianjin Pharmacy, 2011, 23(1): 47-51. [2] 顾小盼, 潘勃, 吴臻, 等. 普洱茶药理作用研究进展[J]. 中国中药杂志, 2017, 42(11): 2038-2041. Gu X P, Pan B, Wu Z, et al.Progress in research for pharmacological effects of pu-erh tea[J]. China Journal of Chinese Materia Medica, 2017, 42(11): 2038-2041. [3] 孟宪钰, 付亚轩, 李明超, 等. 普洱熟茶化学成分研究进展[J]. 食品与发酵工业, 2019, 45(12): 289-294. Meng X Y, Fu Y X, Li M C, et al.Advance in the study on the chemical composition of pu-erh tea[J]. Food and Fermentation Industries, 2019, 45(12): 289-294. [4] Zhou Z H, Zhang Y J, Xu M, et al.Puerins A and B, two new 8-C substituted flavan-3-ols from pu-er tea[J]. Journal of Agricultural and Food Chemistry, 2005, 53(22): 8614-8617. [5] 东方, 杨子银, 何普明, 等. 普洱茶抗氧化活性成分的LC-MS分析[J]. 中国食品学报, 2008, 8(2): 133-141. Dong F, Yang Z Y, He P M, et al.Liquid chromatographic-mass spectrometric analysis of antioxidant compounds from pu-erh tea[J]. Journal of Chinese Institute of Food Science and Technology, 2008, 8(2): 133-141. [6] Wang W, Zhang L, Wang S, et al.8-C N-ethyl-2-pyrrolidinone substituted flavan-3-ols as the marker compounds of Chinese dark teas formed in the post-fermentation process provide significant antioxidative activity[J]. Food Chemistry, 2014, 152: 539-545. [7] 顾小盼, 吴臻, 靳凤玉, 等. 普洱茶素Ⅰ改善糖脂代谢紊乱的药效评价及作用机制研究[J]. 中国中药杂志, 2018, 43(11): 2339-2344. Gu X P, Wu Z, Jin F Y, et al.Efficacy and mechanism of puerin Ⅰ in improving disorder of glycolipid metabolism in ApoE-/- mice[J]. China Journal of Chinese Materia Medica, 2018, 43(11): 2339-2344. [8] 王鑫玉, 赵一慕, 高云, 等. 普洱茶素Ⅱ改善高脂血症ApoE-/-小鼠动脉粥样硬化作用机制研究[J]. 中草药, 2023, 54(4): 1157-1163. Wang X Y, Zhao Y M, Gao Y, et al.Mechanism of puerin Ⅱ on improving atherosclerosis in ApoE-/- mice with hyperlipidemia[J]. Chinese Traditional and Herbal Drugs, 2023, 54(4): 1157-1163. [9] Gu X P, Meng Y X, Jin F Y, et al.Puerin III alleviates glucose and lipid metabolism disorders in high-fat high-sucrose diet-induced hyperlipidemic and hyperglycemic ApoE-/-mice[J]. Journal of Functional Foods, 2022, 93: 105085. doi: 10.1016/j.jff.2022.105085. [10] Ye F, Dewanjee S, Li Y H, et al.Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer[J]. Molecular Cancer, 2023, 22(1): 105. doi: 10.1186/s12943-023-01805-y. [11] Siegel R L, Miller K D, Wagle N S, et al.Cancer statistics, 2023[J]. CA: A Cancer Journal for Clinicians, 2023, 73(1): 17-48. [12] Feng Y X, Spezia M, Huang S F, et al.Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis[J]. Genes & Diseases, 2018, 5(2): 77-106. [13] Sviderskiy V O, Blumenberg L, Gorodetsky E, et al.Hyperactive CDK2 activity in basal-like breast cancer imposes a genome integrity liability that can be exploited by targeting DNA polymerase ε[J]. Molecular Cell, 2020, 80(4): 682-698. [14] 陈安莉, 沈浩元, 舒王. 三阴性乳腺癌新辅助治疗的临床研究进展[J]. 现代肿瘤医学, 2023, 31(3): 566-571. Chen A L, Shen H Y, Shu W.Neoadjuvant therapy for triple negative breast cancer: clinical progress[J]. Modern Oncology, 2023, 31(3): 566-571. [15] Xie J, Yu H S, Song S, et al.Pu-erh tea water extract mediates cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells[J]. Frontiers in Pharmacology, 2017, 8: 190. doi: 10.3389/fphar.2017.00190. [16] 杨潇, 龙汉安, 肖秀丽. 不同分子亚型乳腺癌临床特征及治疗策略研究进展[J]. 牡丹江医学院学报, 2013, 34(2): 76-78. Yang X, Long H A, Xiao X L.Research progress on clinical characteristics and treatment strategies of different molecular subtypes of breast cancer[J]. Journal of Mudanjing Medical University, 2013, 34(2): 76-78. [17] 王烈, 黎成金. 乳腺癌治疗方法的变迁[J]. 中国临床医生, 2011, 39(7): 12-14. Wang L, Li C J.Changes of treatment methods for breast cancer[J]. Chinese Journal for Clinicians, 2011, 39(7): 12-14. [18] Zhao L J, Jia S T, Tang W R, et al.Pu-erh tea inhibits tumor cell growth by down-regulating mutant p53[J]. International Journal of Molecular Sciences, 2011, 12(11): 7581-7593. [19] Zhao H, Zhang M, Zhao L, et al.Changes of constituents and activity to apoptosis and cell cycle during fermentation of tea[J]. International Journal of Molecular Sciences, 2011, 12(3): 1862-1875. [20] 韩莎莎, 高雄, 林晓蓉, 等. 普洱茶挥发性组分的抗癌、抗炎功能特性[J]. 食品工业科技, 2019, 40(3): 97-105. Han S S, Gao X, Lin X R, et al.Anti-cancer and anti-inflammatory activities of volatile components from pu-erh tea[J]. Science and Technology of Food Industry. 2019, 40(3): 97-105. [21] 赵航, 盛婧雪, 李洪广, 等. 普洱茶提取物对宫颈癌hela细胞的诱导凋亡作用[J]. 中国生物制品学杂志, 2011, 24(2): 137-140. Zhao H, Sheng J X, Li H G, et al.Induction of apoptosis of hela cells with pu-erh tea extracts[J]. Chinese Journal of Biologicals, 2011, 24(2): 137-140. [22] Zhao X, Qian Y, Zou Y L, et al.Pu-erh tea has in vitro anticancer activity in TCA8113 cells and preventive effects on buccal mucosa cancer in U14 cells injected mice in vivo[J]. Nutrition and Cancer, 2014, 66(6): 1059-1069. |